Alnylam has entered into a partnership with the scientist instrumental in developing the technology behind ChatGPT, agreeing to pay $30 million upfront to collaborate with Jakob Uszkoreit’s Inceptive Nucleics on AI-driven drug design.
Since its launch, the biotech has secured $120 million in funding from investors, including Nvidia, across financing rounds in 2021 and 2023.
After applying its artificial intelligence capabilities to sequence-based medicines such as small interfering RNA (siRNA), Inceptive has now secured a collaboration with one of the leaders in the field. Under the agreement, Alnylam will pay $30 million upfront and could provide as much as $2 billion in preclinical, regulatory and economic milestone payments.
Inceptive has trained its AI models using sequence, functional and structural biological data. By integrating multiple forms of information, the startup seeks to develop systems capable of recognizing biological patterns and applying insights broadly across different scientific challenges. The company believes this adaptability could allow its models to transition between therapeutic approaches without requiring retraining.
Before formalizing the collaboration, Alnylam conducted investigative work with Inceptive and found that the AI model adapted to projects within weeks while producing biological findings from comparatively modest datasets used to characterize siRNA. These early findings encouraged Alnylam to expand the relationship into a formal partnership focused on siRNA design.
The companies intend to model target messenger RNAs, investigate sequence possibilities and assess innovative chemical modifications aimed at improving drug strength and effectiveness. Alnylam will then continue development of the candidates predicted to perform best.
The agreement marks a broader expansion of Alnylam’s use of artificial intelligence. During a Morgan Stanley event in September 2025, the company’s Chief Financial Officer, Jeffrey Poulton, indicated that Alnylam had already been using AI to examine genetic databases for target discovery. At the time, Poulton suggested that identifying new therapeutic targets represented one of the company’s key areas of AI investment and implied that additional initiatives could follow.
Alnylam joins a growing list of biopharmaceutical companies deepening their involvement in AI-driven research. In recent weeks, Incyte signed agreements with Genesis and Edison Scientific, Bristol Myers Squibb formed a partnership with Anthropic (the developer of Claude) and Alphabet-backed Isomorphic Labs secured over $2 billion in funding.
The agreement represents another example of how artificial intelligence is increasingly transforming the pharmaceutical sector, among others. Supporters of the technology argue that AI can accelerate the identification of the most promising therapies, reducing the time needed to advance drug development. Uszkoreit suggested that the company’s technology, when combined with Alnylam’s expertise, has the potential to reshape how scientists understand biological systems and develop treatments aimed at improving human health by understanding the complex biological patterns and turning data into useful insights.
Alnylam has announced a landmark $2 billion collaboration agreement with Inceptive, marking a significant step forward in the application of artificial intelligence to RNA-based drug development. Through the partnership, Alnylam aims to enhance the design and optimization of small interfering RNA (siRNA) therapies by leveraging advanced AI technologies capable of accelerating discovery and improving development efficiency.
The agreement highlights the growing convergence of biotechnology and artificial intelligence as companies seek innovative ways to develop next-generation therapeutics faster and more effectively.
Alnylam Strengthens Its RNAi Leadership Position
As a pioneer in RNA interference (RNAi) therapeutics, Alnylam has built a strong reputation for advancing innovative treatments that target disease at the genetic level. The new collaboration reinforces Alnylam’s commitment to maintaining leadership in RNA-based medicine while exploring emerging technologies that can unlock new therapeutic opportunities.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
